logo.jpg
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
03. November 2023 14:00 ET | ImCheck Therapeutics SAS
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...
Turnstone Logo.jpg
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
03. November 2023 06:00 ET | Turnstone Biologics Corp.
Posters showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.
Larkspur Biosciences.png
Larkspur Biosciences to Present New Mechanistic Data on the Role of Pin1 in Modulating the Fibroblast – Cancer Axis at SITC 2023
25. Oktober 2023 08:00 ET | Larkspur Biosciences, Inc.
WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a biotechnology company building precision therapies to outsmart cancer, announced that data supporting development of a...